All women with breast cancer who require or choose mastectomy should have equitable access to safe breast reconstruction as an essential component of comprehensive care. Although textured breast implants have received substantial scrutiny since a description of their association with anaplastic large cell lymphoma (ALCL),1 their implication for breast cancer outcomes has not been reported to date. The novel observation by Lee and colleagues2 in this issue of JAMA Surgery warns that textured implants may confer an increased risk of breast cancer recurrence compared with smooth implants. Larger, multi-institutional analysis is critical to confirming the findings, but the preliminary data presented in the study by Lee et al2 are both alarming and intriguing.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Cassidy MR, Roh DS. Is It Time to Abandon Textured Breast Implants for Breast Cancer Reconstruction? JAMA Surg. Published online October 07, 2020. doi:10.1001/jamasurg.2020.4141
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: